CONMED Corporation Announces Fourth Quarter and Full-Year 2018 Financial Results

Go back to CONMED Corporation Announces Fourth Quarter and Full-Year 2018 Financial Results

CONMED (CNMD) PT Lowered to $79 at Needham & Company

January 23, 2019 7:34 AM EST

Needham & Company analyst Mike Matson lowered the price target on CONMED (NASDAQ: CNMD) to $79.00 (from $86.00) while maintaining a Buy rating.

The analyst commented, "CNMD's 4Q18 revenue beat consensus while its EPS was in line with consensus. Management provided 2019 revenue and EPS guidance that... More

Conmed (CNMD) Tops Q4 EPS by 1c, Offers FY Guidance

January 22, 2019 4:03 PM EST

Conmed (NASDAQ: CNMD) reported Q4 EPS of $0.73, $0.01 better than the analyst estimate of $0.72. Revenue for the quarter came in at $242.4 million versus the consensus estimate of $228.8 million.

GUIDANCE:

Conmed sees FY2019 EPS of $2.42-$2.47, versus the consensus of $2.42.

The... More